InsiderTrades.com logo

ROQ Insider Trading

Insider Ownership Percentage: 60.40%
Insider Buying (Last 12 Months): £12,000
Insider Selling (Last 12 Months): GBX 0

Roquefort Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Roquefort Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Roquefort Therapeutics Share Price & Price History

Current Price: GBX 1.71
Price Change: ▼ Price Decrease of -0.137 (-7.41%)
As of 04/17/2025 12:22 PM ET

This chart shows the closing price history over time for ROQ up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Roquefort Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/4/2025Stephen Paul WestInsiderBuy400,000GBX 3£12,000
8/1/2023Dr Darrin DisleyInsiderBuy269,935GBX 7£18,895.45
7/12/2023Stephen Paul WestInsiderBuy15,730GBX 6£943.80
6/26/2023Stephen Paul WestInsiderBuy144,117GBX 7£10,088.19
6/23/2023Trevor Ajanthan (Ajan) ReginaldInsiderBuy35,265GBX 7£2,468.55
9/26/2022Dr Darrin DisleyInsiderBuy515,913GBX 8£41,273.04
7/4/2022Stephen Paul WestInsiderBuy210,000GBX 9£18,900
6/30/2022Stephen Paul WestInsiderBuy55,147GBX 9£4,963.23
See Full Table

SEC Filings (Institutional Ownership Changes) for Roquefort Therapeutics (LON:ROQ)

1.74% of Roquefort Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Roquefort Therapeutics logo
Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.
Read More on Roquefort Therapeutics

Today's Range

Now: GBX 1.71
Low: 1.71
High: 1.84

50 Day Range

MA: GBX 1.89
Low: 1.52
High: 2.64

52 Week Range

Now: GBX 1.71
Low: 1.40
High: 6.78

Volume

103,283 shs

Average Volume

2,879,991 shs

Market Capitalization

£2.18 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.05

Who are the company insiders with the largest holdings of Roquefort Therapeutics?

Roquefort Therapeutics' top insider investors include:
  1. Dr Darrin Disley (Insider)
  2. Stephen Paul West (Insider)
  3. Trevor Ajanthan (Ajan) Reginald (Insider)
Learn More about top insider investors at Roquefort Therapeutics.